Mutations in an important metabolic enzyme—IDH—are a common driver of blood cancer, especially certain types of lymphoma and leukemia. To better understand how these mutations drive the formation of cancer, Dr. Julie Leca is utilizing mouse models that possess IDH mutations as well as mutations in other relevant genes. Specifically, she will be characterizing how these mutations influence the ability of cells to repair their own DNA, which can be a crucial factor in the development of cancer. In addition to mouse models, Dr. Leca will be working with human samples to determine the effectiveness of IDH-blocking drugs as well as drugs that target DNA repair molecules. Her ultimate goal is to identify the factors involved in either response or resistance to these therapies, which could pave for the development of strategies to help patients in the clinic.
Projects and Grants
Therapeutic implications of altered epigenetics and DNA damage responses in IDH2-mutated hematologic diseases
University Health Network (Canada) | Leukemia, Lymphoma | 2017 | Tak W. Mak, Ph.D.
Let's spread the word about Immunotherapy! Click to share this page with your community.